h***s://www.********.au/2021/12/21/heres-why-the-race-oncology-asxrac-share-price-is-edging-higher/

Here’s why the Race Oncology (ASX:RAC) share price is edging higher

The pharmaceutical company’s shares are picking up steam on Tuesday. Here are the details

The Race Oncology Ltd (ASX: RAC) share price is climbing today on the back of the company’s latest capital raise.

During morning trade, the pharmaceutical company’s shares are up 3.64% to $3.42 apiece.

What did the company announce?

Investors are driving up the Race Oncology share price following the company’s strongly supported share purchase plan (SPP).

According to its release, Race Oncology advised it has successfully completed its SPP, raising $29.7 million after a scale back. This represents around 6.6% of the company’s issued capital as of today. The offer received strong support from 2,340 shareholders, who applied for more than $43.9 million under the SPP.

The retail component of the company’s equity raising efforts will see 9.9 new million shares created at $3 each.

The funds raised will go towards a number of company programs. These include:

• Phase 1b/2 FTO solid tumour clinical trial ($8 million);
• Cardio-protection Phase 2b clinical trial in breast cancer patients ($7.5 million);
• Phase 2 EMD AML/MDS clinical trial in Europe ($9.2 million);
• Improved formulations of Zantrene ($3.2 million);
• Preclinical cardio-protection studies ($1 million); and
• Development of new molecules ($0.8 million).

The SPP shares are expected to be issued today, and be available for trading from tomorrow.

Race Oncology managing director and CEO Phil Lynch commented:

The number of applications reflects enthusiasm for the significant potential of our lead drug Zantrene, and this enables us to implement our planned clinical and drug development plans across the three-pillar program. We move into 2022 in an exceptional position, with many critical, reportable milestones ahead of us.